EGLE-THERAPEUTICS-SAS
11.6.2020 13:32:11 CEST | Business Wire | Press release
Egle Therapeutics SAS, an emerging biotechnology company focused on developing first-in-class immunotherapies targeting immune suppressor regulatory T-cells for oncology and autoimmune diseases, announced today a corporate strategic research alliance with Takeda Pharmaceutical Company Limited (“Takeda”) with the goal of validating novel tumor-infiltrating regulatory T-cell (Treg) targets against which Takeda will develop potential therapies.
As a newly established bioscience company spun out of Institut Curie in the field of Treg immune modulation, Egle Therapeutics has assembled a proprietary translational based target discovery engine leveraging patient samples to map out - at the single cell level - unique transcriptomic signatures and targets specific for tumor-infiltrating Treg sub-populations. Capitalizing on these newly identified tumor-infiltrating Treg targets, the company is building a proprietary Treg modulating drug pipeline which also includes computationally designed resurfaced IL-2 proprietary variants, featuring unique mechanism of action to engage or dis-engage Tregs.
Under the terms of the agreement, Egle Therapeutics will lead target validation efforts on a subset targets Egle has identified and Takeda will be responsible for the development, manufacturing, and commercialization of resulting therapies. Egle Therapeutics will receive an upfront payment and research funding, and will be eligible to receive additional development and sales milestone payments based on the exclusivity of targets selected by Takeda.
Luc Boblet, co-founder and CEO of Egle Tx, commented “We are thrilled to engage with Takeda to fully exploit the great therapeutic potential of inhibiting the most immunosuppressive arm of immunity to restore antitumor immune response. We believe that joining forces would be the most efficient path to successfully develop novel generation of anti-Treg immunotherapies for the benefit of patients.”
“Working with Egle to leverage the unique translational derived patient data bringing tumor-specific Treg targets is an exciting prospect to further advance our immuno-oncology drug discovery efforts,” said Loïc Vincent, Head, Oncology Drug Discovery Unit at Takeda. “Targeting tumor-infiltrating regulatory T-cells to overcome the immune suppression in tumor microenvironments will complement our current immuno-oncology approaches and help advance an exciting portfolio.”
In addition to the funding of the multi-target research collaboration, Takeda will invest €4.6 million in convertible debt through its venture arm, Takeda Ventures, Inc. (“TVI”), to support Egle’s corporate growth and internal programs on IL-2-based Treg modulation. Egle’s flagship program pioneers the dis-engagement of tumor-infiltrating Treg through unique proprietary series of IL-2 variants that act as IL-2 antagonists.
“While the whole competition converges solely on a similar approach to enhance effector T cells by disrupting binding of IL-2 to Tregs, our IL-2 variants conserve intact IL-2 binding to CD25, conferring a unique mechanism of action for starving Treg from endogenous IL-2, while leaving active the CD8+ effector T cell arm of the immune response,” Luc Boblet added. “Takeda’s equity commitment will help Egle’s launch strikingly hit the road building on our excellent scientific foundation.”
About Egle Therapeutics
Established in early 2020, as a spin-out of Institut Curie by Luc Boblet, serial biotech entrepreneur (former co-founder and CEO of PathoQuest, and former co-founder and CEO of H-Immune sold to HifiBio Therapeutics) and Dr Eliane Piaggio, PhD, renowned immunologist in the Treg / IL-2 field (INSERM Research Director, Head of the Translational Immunotherapy Team – TransImm – at Institut Curie), Egle Therapeutics is developing first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases.
The key element of Egle’s core approach is the leveraging of its translational-based target discovery engine to unveil novel therapeutic Treg targets and vectorize computationally designed resurfaced cytokines acting as antagonists or as selective Treg-agonists. Egle’s flagship program pioneers dis-engagement of tumor-infiltrating Tregs through a proprietary series of IL-2 variants featuring a unique antagonism mechanism of action.
To find out more about Egle Therapeutics, please visit www.egle-tx.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200611005040/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Redslim expands into Asia-Pacific to support global brands with data and AI infrastructure12.3.2026 07:00:00 CET | Press release
Redslim, a specialist in end-to-end data management solutions and an Astorg portfolio company, today announced its expansion into the Asia-Pacific region and the appointment of Kyriakos Zannikos as Regional Director, APAC. The move marks an important milestone in Redslim’s global growth strategy and brings the company closer to clients operating in one of the world’s fastest-growing and most data-driven consumer markets. As global consumer brands accelerate digital transformation and AI adoption, many organizations still struggle with fragmented data ecosystems spanning multiple agencies, markets and datasets. These challenges are particularly pronounced in Asia-Pacific, where diverse market structures and rapid growth create complex data environments. Redslim helps organizations transform fragmented market information into valuable data assets, empowering clients to make confident decisions and unlock the full value of their data. By building strong data foundations, Redslim supports
Meiji Seika Pharma Initiates Phase I Clinical Trial in Australia Evaluating ME3241, an Anti-PD-1 Agonist Antibody Discovered Through Collaborative Research With FBRI12.3.2026 07:00:00 CET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) announced today that it has initiated a Phase I clinical trial of ME3241 (development code), an anti-PD-1 agonist monoclonal antibody discovered through collaborative research with the Foundation for Biomedical Research and Innovation at Kobe (Headquarters: Kobe, Japan; President: Shuh Narumiya; hereinafter “FBRI”). The Phase I clinical trial is designed as a randomized, placebo-controlled, double-blind study, with the objective of evaluating the safety and tolerability of ME3241 following single and multiple dosing, as well as its pharmacokinetics and pharmacodynamics (ClinicalTrials.gov: NCT07422207). ME3241 was discovered through a collaborative research program led by Program Director Tasuku Honjo, a professor emeritus at Kyoto University. PD-1 is a molecule expressed on activated T cells and other lymphocytes that suppresses immune responses. Through this re
Andersen Consulting styrker sin platform med samarbejdsvirksomheden Ambit Iberia12.3.2026 05:55:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med Ambit Iberia, et konsulentfirma, der specialiserer sig i digitale og regulatoriske løsninger til life science-sektoren. Ambit Iberia, der blev stiftet i 2003, har hovedsæde i Spanien og leverer integrerede løsninger inden for rådgivning, teknologi og rekruttering til medicinal-, bioteknologi- og medtechvirksomheder. Virksomheden hjælper kunder med at opfylde skiftende standarder for kvalitet, compliance og lovgivning gennem ydelser, der spænder over regulatoriske anliggender, dataintegritet, validering af it-systemer og digital transformation. Med mere end 20 års brancheerfaring tilbyder Ambit Iberia også ydelser inden for human capital og executive search, der forbinder organisationer med specialiserede fagfolk og topledertalenter, hvilket øger effektiviteten og fremmer bæredygtig vækst i et stærkt reguleret miljø. "Vores fokus har altid været at levere speciali
EIG’s MidOcean Energy to Acquire Additional Gorgon LNG Interest from JERA; Parties Explore Strategic Alliance12.3.2026 03:14:00 CET | Press release
Transaction increases MidOcean’s equity exposure to premier Australian LNG project Adds incremental uncontracted LNG volumes, enhancing portfolio optimization and marketing flexibility Planning future collaborations, exploring further transactions and opportunities with JERA across other assets globally with the aim of creating a future strategic alliance MidOcean Energy (“MidOcean”), a liquefied natural gas (LNG) company formed and managed by EIG, today announced it has entered into definitive agreements with JERA Co., Inc. (“JERA”) to acquire JERA Gorgon Pty Ltd, which holds JERA’s 0.417% interest in the Gorgon LNG project. MidOcean is an existing participant in the Gorgon LNG project, and this transaction increases MidOcean’s interest in Gorgon to 1.417%. The transaction perimeter also includes JERA’s 0.735% interest in the Ichthys LNG project. Subject to the satisfaction of relevant conditions precedent, the interests in Gorgon and Ichthys will be sold to MidOcean, and then the Ich
DCX Launches Comprehensive ECDU Portfolio – Enterprise-Class Coolant Distribution Units From 600 kW to 2.6 MW11.3.2026 16:34:00 CET | Press release
DCX Liquid Cooling Systems today unveiled its new ECDU (Enterprise Coolant Distribution Unit) platform, a family of three purpose-built CDU models that deliver real cooling capacities from 600 kW to 2.6 MW in industry-standard rack and in-row footprints. The portfolio has been engineered specifically for the accelerating transition to direct-to-chip liquid cooling in high-density enterprise, colocation, cloud, and hyperscale AI environments where thermal stability, uptime, and cost-efficiency are non-negotiable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311214891/en/ DCX ECDU, the new generation of Enterprise Coolant Distribution Units dedicated to HPC and AI deployments. The lineup consists of: Enterprise ECDU 1380/2600 V1 - Delivers 1.38–2.6 MW of actual cooling capacity (based on real-world secondary-loop conditions). Single-pump configuration reaches flow rates up to 3,333 liters per minute (lpm). Mission Critica
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom